Benzodiazepines in anxiety disorders

JAMA Psychiatry

Volumn 72, Issue 7, 2015, Pages 733-734

  Fava, Giovanni A ^a   Balon, Richard ^b,c   Rickels, Karl ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; DRUG ABUSE; DRUG EFFICACY; HUMAN; LETTER; PRACTICE GUIDELINE; PRESCRIPTION; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; STATISTICS AND NUMERICAL DATA;

BENZODIAZEPINES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE;

EID: 84936823400     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.0182     Document Type: Letter

References (5)

1. Moore N, Pariente A, Bégaud B. Why are benzodiazepines not yet controlled substances? JAMA Psychiatry. 2015;72(2):110-111.
2. Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 2013;82(6):355-362.
3. Task Force Report of the American Psychiatric Association. Benzodiazepine Dependence, Toxicity, and Abuse.Washington, DC: American Psychiatric Association; 1990.
4. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? a comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction. 2012;107(5):900-908.
5. Cerovecki A, Musil R, Klimke A, et al.Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs. 2013;27 (7):545-572.